HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $55 price target.